Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
LPTX 
Leap Therapeutics Inc (LPTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: LPTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $3
1 Year Target Price $3
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -61.15% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 13.15M USD | Price to earnings Ratio - | 1Y Target Price 3 |
Price to earnings Ratio - | 1Y Target Price 3 | ||
Volume (30-day avg) 1 | Beta -0.22 | 52 Weeks Range 0.22 - 4.79 | Updated Date 09/17/2025 |
52 Weeks Range 0.22 - 4.79 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.58 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -77.23% | Return on Equity (TTM) -183.72% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -4938094 | Price to Sales(TTM) 160.1 |
Enterprise Value -4938094 | Price to Sales(TTM) 160.1 | ||
Enterprise Value to Revenue 1.9 | Enterprise Value to EBITDA 0.47 | Shares Outstanding 41439500 | Shares Floating 34665824 |
Shares Outstanding 41439500 | Shares Floating 34665824 | ||
Percent Insiders 16.2 | Percent Institutions 22.06 |
Upturn AI SWOT
Leap Therapeutics Inc
Company Overview
History and Background
Leap Therapeutics, Inc. (LPTX) is a biopharmaceutical company focused on developing targeted therapies for cancers. Founded to advance novel cancer treatments, Leap has focused on advancing its pipeline through clinical trials and strategic partnerships.
Core Business Areas
- Development of DKN-01: Leap's primary focus is the development of DKN-01, a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. DKN-01 is being evaluated in various clinical trials for different cancer types.
- Partnerships and Licensing: Leap engages in partnerships and licensing agreements to support the development and commercialization of its products. These collaborations are essential for funding clinical trials and expanding its reach.
Leadership and Structure
Leap Therapeutics is led by a management team with experience in drug development and commercialization. The organizational structure includes departments focused on research and development, clinical trials, regulatory affairs, and finance.
Top Products and Market Share
Key Offerings
- DKN-01: DKN-01 is Leap's lead product candidate, a humanized monoclonal antibody targeting DKK1. It is currently in clinical trials for various cancers, including esophagogastric, biliary tract, endometrial, and colorectal cancers. Leap is seeking FDA approval for its use. Competitors include companies developing therapies targeting similar pathways or cancer types (e.g., antibody-drug conjugates, other targeted therapies). Market share data is not yet applicable as DKN-01 is not yet approved for commercial use.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, regulatory hurdles, and intense competition. Companies focus on developing innovative therapies for various diseases, including cancer.
Positioning
Leap Therapeutics is positioned as a company focused on developing targeted therapies for cancers. Its competitive advantage lies in its DKN-01 antibody and its potential to address unmet medical needs in specific cancer types.
Total Addressable Market (TAM)
The total addressable market for cancer therapies is substantial, estimated in the hundreds of billions of dollars globally. Leap is positioned to capture a portion of this market with DKN-01, particularly if clinical trials demonstrate efficacy in specific cancer indications.
Upturn SWOT Analysis
Strengths
- Novel DKK1-targeting antibody (DKN-01)
- Clinical trials underway in multiple cancer types
- Experienced management team
- Strategic partnerships for funding and development
Weaknesses
- Reliance on a single lead product candidate
- High cash burn rate due to R&D expenses
- Dependence on clinical trial outcomes
- Competition from larger pharmaceutical companies
Opportunities
- Positive clinical trial results for DKN-01
- Expansion of DKN-01 into new cancer indications
- Potential for FDA approval and commercialization of DKN-01
- Acquisition by a larger pharmaceutical company
Threats
- Failure of clinical trials for DKN-01
- Competition from other cancer therapies
- Regulatory hurdles and delays
- Economic downturn affecting funding availability
Competitors and Market Share
Key Competitors
- MRK
- BMY
- AZN
- GILD
Competitive Landscape
Leap Therapeutics faces competition from larger pharmaceutical companies with greater resources and established products. Its competitive advantage lies in the novelty of DKN-01 and its potential to address unmet medical needs.
Growth Trajectory and Initiatives
Historical Growth: Leap's historical growth is characterized by advancing its lead product candidate through clinical trials.
Future Projections: Future growth is dependent on the success of DKN-01 and its potential commercialization. Analyst estimates vary based on clinical trial outcomes and regulatory approval.
Recent Initiatives: Recent initiatives include enrolling patients in clinical trials for DKN-01, presenting data at medical conferences, and seeking partnerships.
Summary
Leap Therapeutics is a clinical-stage biopharmaceutical company primarily focused on the development of DKN-01. Positive clinical trial results are essential for future growth. The company is still quite speculative due to its stage, and faces substantial competition. Successful partnerships and careful cash management will be key.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Leap Therapeutics Inc. SEC Filings
- Leap Therapeutics Inc. Investor Relations
- Analyst Reports (where available)
- Industry Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on your own research and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Leap Therapeutics Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2017-01-25 | CFO, General Counsel, Treasurer & Secretary, President, CEO & Director Mr. Douglas E. Onsi J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 52 | Website https://www.leaptx.com |
Full time employees 52 | Website https://www.leaptx.com | ||
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-501, a monoclonal antibody that inhibits GDF-15 protein that is in preclinical trial. It has an option and license agreement with Adimab, LLC and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.